Here's why you should be investing in high-price stock - Abbott India. #HighPricePhobia
https://t.co/NS2NtZGAMz
— ET NOW (
@ETNOWlive
) November 5, 2015
Disclosure: Recency bias and may accumulate more
Here's why you should be investing in high-price stock - Abbott India. #HighPricePhobia
https://t.co/NS2NtZGAMz
— ET NOW (
@ETNOWlive
) November 5, 2015
Disclosure: Recency bias and may accumulate more
Giving rank by Senior VP members will entail its own problems.
It will at the end of the day be a subjective assessment and opinion.
Plus how many threads will these senior members go thru in an effort to give these ranks or marks.
As mentioned before most Senior VP members wont have the time or inclination to go through these companies. They would obviously have better things to do than read and research these things before giving out opinioins.
I think wherever any member feels that some kind of abuse of forum is going on he/she can flag the post to bring it to moderator attention and then action can be taken if needed.
In fact these kind of operations are ways for investors to educate themselves on how to avoid potential minefields. That is often as important as the search for multibaggers.
avanti results again are a mixed bag. bottomline great, topline flat
Total Income flat at 532 cr vs 531 cr y-on-y
Domestic sales up from 439 to 449 crores.
Exports down from 90 cr to 77 cr.
OP up from 51 to 60 crores.
NP up from 34 to 44 crores.
EPS up from 37.6 to 48.4
Half yearly eps at 98.73 per share.
Co looks to be on track to achieve EPS in the vicinity of 200 per share. (or nearabout)
Long term borrowing at 3 crores. Current investments at 111 crores and cash and equivalents at 13 crores.
Net cash balance sheet.
disc: invested and occupies more than 10 of PF.
http://corporates.bseindia.com/xml-data/corpfiling/AttachLive/7BAA6E5A_D907_46ED_9448_89C66A3B88EC_175243.pdf
Q2 results are out
Flat topline
Good growth in NP 44cr vs 34 cr EPS 48.4 vs 37.6
Sub 10% RoE for the past 3 years, and also in H1 FY 16. Higher provisioning norms has diluted the effect of higher operating leverage. Operating Income / Average Assets however has risen significantly - would this be due to higher growth of consumer durable financing?
the FCF is not 17 Cr but 17.61cr - 11.27cr (Capex) = 6.34 cr ( March 2015 AR). But yes its undervalued - its earning a FCF yield of 20%+ on the EV of 30cr (74 cap - 45 cr investments & cash)
Hi Rohit,
You can search about patent expiry for ANDAs on Orange book (for biologicals you have purple book which is available in pdf) which is their USFDA website. There you can type the molecule name and get data about the patent expiry.
I dont have much clarity about when the generic can be launched on exclusivity expiry or patent expiry. Actually, it varies from molecule to molecule. A drug can have various patent and exclusivity expiry dates. Even in exclusivity, there are various classifications like New Chemical Entity, Paediatric drug, Orphan Drug etc and an extension is given in case of any of these classifications (extension beyond the regular 5 years of exclusivity). Also, there can be some agreement which a generic player can enter with innovator eg Alembic has USFDA approval for gPristiq but hasnt launched it yet as per agreement with innovator because of various issues like litigations etc. I usually google about generic entry of a specific molecule. But still too difficult to predict.
Hi Sta,
I havent looked at Auro, so cant comment.
Hi @ankitgupta
I am trying to understand exclusivity better. I tried to search a bit on USFDA site but didnt understand anything. You said above that the Exclusivity expires on Dec28, 2017 and Patent expires in in Dec 2019. So what happens in the period in between?
Is it so that no one can even file and ANDA for a drug that is under exclusivity?
EvoLve theme by Theme4Press • Powered by WordPress & Rakesh Jhunjhunwala Latest Stock Market News
The Most Valuable Commodity Is Information!